3Moroos SK, Thomsen HS. European Society of urogenital radlology guide- lines on adndmstenng [ J ]. Abdom Imaging, 2003,28 (2) : 187 - 190. 被引量：1
4Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid's clinical safety and tolerabitity: comparator -controlled phase I- II studies. Antimicrob Agents Chemother, 2003,47 (6) : 1 824 - 1 831. 被引量：1
5Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and phar- macodynamie analysis of linezolid and a hematologic side effect, thrombo- cytopenia, in Japanese patients [ J ]. Antimicrob Agents Chemother, 2011, 55(5) :1 867- 1 873. 被引量：1
6Vinh DC, Rubinstein E. Linezolid : a review of safety and tolerability [ J ]. ] Infect,2009,59 (Suppl 1 ) : S59 - S74. 被引量：1
7Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid - associated thrombocytopenia among patients with renal insufficiency [ J ]. Int J Antimi- crob Agents, 2006,28 (4) : 345 - 351. 被引量：1
8Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience [J]. Antimicrob Agents Chemother, 2002, 46(8) :2 723 - 2 726. 被引量：1
